Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Quarterly Activities/Appendix 4C Cash Flow Report

Tuesday, April 29, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has announced significant progress, including receiving IND approval from the US FDA for its Phase I study targeting B7H3 with BetaBart (RV-01). The company has also dosed its first patient in the Phase 1/2a clinical study of BetaBart. Additionally, positive updates have been shared across four of its clinical programs.
Price reaction · baseline $3.99 (2025-04-28 close) · hit pre-market · clean, no other RADX news in the window
day 0 close
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has received IND approval from the US FDA.
  • The company is initiating a Phase I therapeutic clinical study.
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Announcements
• Price Sensitive
• April 29, 2025
Loading Viewer…

More Announcements & Updates

• Updates
• October 20, 2023
• Announcements
• December 8, 2021
• Announcements
• November 21, 2023
• Announcements
• September 20, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent approval did Radiopharm Theranostics receive?

Radiopharm Theranostics received IND approval from the US FDA.

What is the focus of the Phase I study by Radiopharm?

The Phase I study targets B7H3 with BetaBart (RV-01).

What significant milestone has Radiopharm achieved recently?

Radiopharm has dosed its first patient in the Phase 1/2a clinical study.

How many clinical programs has Radiopharm updated?

Radiopharm has provided positive updates across four clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1 study FDA approval B7H3
Last updated: Apr 29, 2025